Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-250-0111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$194.03 million
Profitability
Miscellaneous
Employees548
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) released its earnings results on Thursday, August, 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. The biotechnology company had revenue of $70.70 million for the quarter, compared to analyst estimates of $65.47 million. Repligen had a net margin of 11.42% and a return on equity of 6.92%. Repligen's revenue for the quarter was up 48.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY19 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of $0.94-0.98 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.96. The company issued revenue guidance of $264-268 million, compared to the consensus revenue estimate of $255.79 million.
What price target have analysts set for RGEN?
7 equities research analysts have issued 1-year target prices for Repligen's stock. Their predictions range from $70.00 to $110.00. On average, they expect Repligen's share price to reach $101.00 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price. View Analyst Price Targets for Repligen.
What is the consensus analysts' recommendation for Repligen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.
What are Wall Street analysts saying about Repligen stock?
Here are some recent quotes from research analysts about Repligen stock:
- 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019)
- 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019)
Has Repligen been receiving favorable news coverage?
News articles about RGEN stock have been trending negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of Repligen own?
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
- Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director of Investor Relations
- Mr. Stephen Tingley, VP of Sales
Who are Repligen's major shareholders?
Repligen's stock is owned by a number of of institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (0.45%), Pacer Advisors Inc. (0.03%), State of Alaska Department of Revenue (0.02%) and Redhawk Wealth Advisors Inc. (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which institutional investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC and State of Alaska Department of Revenue. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Ralf Kuriyel and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which institutional investors are buying Repligen stock?
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $77.46.
How big of a company is Repligen?
Repligen has a market capitalization of $3.99 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.
What is Repligen's official website?
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
